Picture [iito] Made Without Love 650x80px
Document › Details

Bone Therapeutics S.A.. (10/29/18). "Press Release: Bone Therapeutics Announces Appointment of Linda Lebon as Chief Regulatory Officer". Gosselies.

Organisations Organisation Bone Therapeutics S.A. (Euronext Brussels + Paris: BOTHE)
  Group Bone Therapeutics (Group)
  Organisation 2 Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
  Today Argenx SE (Euronext + Nasdaq: ARGX)
  Group Argenx (Argen-X) (Group)
Products Product regulatory services
  Product 2 ALLOB® allogeneic bone cell product
Persons Person Lebon, Linda (Bone Therapeutics 201810– Chief Regulatory Officer before ArgenX + Quintiles + Voisin Life Sciences)
  Person 2 Lienard, Thomas (Bone Therapeutics 201610– Interim CEO joined 201511– as CBO before Lundbeck + Lilly + McKinsey)

BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that it has appointed Linda Lebon as Chief Regulatory Officer.

Linda Lebon is a strategic regulatory expert with more than 25 years of experience in regulatory affairs. During her career, she has provided regulatory support to companies in strategic global drug development for both clinical and non-clinical projects. Until recently, she was Vice President Regulatory Affairs at argenx, a clinical-stage biotechnology company focused on developing antibodies for autoimmune disease and cancer.

Linda has held positions in several large pharmaceutical companies as well as senior positions in regulatory CROs and advisory firms, including Quintiles and Voisin Life Sciences. As an independent consultant, she has also supported several notable fast-growing life sciences companies including Celyad, Mithra and iTeos Therapeutics, in their product developments in Europe, America and Japan. In these roles she has been closely involved with the transitional process between R&D activities and the regulatory stage of development.

Linda will play a critical role in defining the regulatory pathway for development and clinical programmes and will support the Company as it advances these programmes toward commercialisation.

Thomas Lienard, Chief Executive Officer of Bone Therapeutics, commented: “We are delighted to welcome Linda as our new Chief Regulatory Officer. She is a highly skilled expert in the regulatory field and her extensive experience with strategic drug development makes her an asset to the Executive Team. As our portfolio of therapeutics for orthopaedics and bone diseases moves through advanced clinical development and towards commercialisation, Linda’s understanding of the unique regulatory challenges will be extremely valuable, and her experience puts her in an excellent position to support our programmes through critical regulatory milestones.”

Linda Lebon said: “It is a pleasure to join Bone Therapeutics. The Company has a highly promising portfolio of cell therapy programmes for orthopaedics and bone diseases, which is moving towards catalytic points in clinical and regulatory development, making it an exciting time for me to be joining.”

For further information, please contact:

Bone Therapeutics SA
Thomas Lienard, Chief Executive Officer
Jean-Luc Vandebroek, Chief Financial Officer
Tel: +32 (0) 71 12 10 00

For Belgium Media Enquiries
Laure-Eve Monfort and Sabine Leclercq
Tel: +32 (0)2 290 90 93, +32 (0)2 290 90 91,

For International Media Enquiries
Consilium Strategic Communications
Amber Fennell, Jessica Hodgson, Hendrik Thys and Lindsey Neville
Tel: +44 (0) 20 3709 5701

For French Media and Investor Enquiries
NewCap Investor Relations & Financial Communications
Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau
Tel: + 33 (0)1 44 71 94 94

For US Media and Investor Enquiries
Westwicke Partners
John Woolford
Tel: + 1 443 213 0506

About Bone Therapeutics

Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics’ technology is based on a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.

The Company’s primary clinical focus is ALLOB, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. In addition, the Company also has an autologous bone cell therapy product, PREOB, obtained from patient’s own bone marrow and currently in Phase III development for osteonecrosis of the hip, and JTA-004, a viscosupplement in development for the treatment of knee osteoarthritis.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at:

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Record changed: 2018-11-16


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Bone Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top